Why Bluebird’s Downgrade Sent These Two Rivals Skyrocketing – Investor’s Business Daily
Investor’s Business Daily |
Why Bluebird’s Downgrade Sent These Two Rivals Skyrocketing
Investor’s Business Daily Crispr rallied 4.6%, near 18.70, as Editas popped 3.7%, near 24.90, on Bluebird’s downgrade. All three are working on therapies to treat sickle cell disease, a group of inherited blood disorders. Therapies from Crispr and Editas are showing promise … |
Labiotech.eu (blog) |
CRISPR Gets Snubbed Again by the Nobel Prize Committee
Labiotech.eu (blog) The Nobel Prize Committee has made CRISPR wait at least one more year, as it was pipped by research into the mechanisms underlying circadian rhythm. The 2017 Nobel Prize in Physiology or Medicine has been awarded to Jeffrey C. Hall, Michael … Nobel Prize 2017: Free Beer, Free Parking and Other Perks Winners Can ExpectNewsweek Here’s How The Body Keeps Time, Thanks to This Year’s Nobel Winning ScienceGizmodo Nobel 2017 season opens with medicine prizeDigital Journal |
Myeloma Research News |
Patient Recruitment Begins for Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
Myeloma Research News A Phase 1 trial sponsored by Poseida Therapeutics for the company’s investigational CAR T-cell therapy for multiple myeloma, P-BCMA-101, is now enrolling participants. The potential therapy specifically targets a molecule found on the surface of … |
Myeloma Research News |
Patient Recruitment Begins for Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
Myeloma Research News A Phase 1 trial sponsored by Poseida Therapeutics for the company’s investigational CAR T-cell therapy for multiple myeloma, P-BCMA-101, is now enrolling participants. The potential therapy specifically targets a molecule found on the surface of … |
Myeloma Research News |
Patient Recruitment Begins for Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
Myeloma Research News A Phase 1 trial sponsored by Poseida Therapeutics for the company’s investigational CAR T-cell therapy for multiple myeloma, P-BCMA-101, is now enrolling participants. The potential therapy specifically targets a molecule found on the surface of … |